FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386310918> ?p ?o ?g. }

• W4386310918 abstract "Immunotherapy with PD-1 inhibitors monotherapy or combined with chemotherapy comprises the first-line palliative treatment for patients with recurrent or metastatic head and neck squamous cell cancers (R/M HNSCC). The established survival advantage among responders is overshadowed by the high percentage of patients failing the standard PD-1 inhibitor-based treatments. Salvage therapies are direly needed. However, no current standards are available. We present the case of a 65-year-old patient with heavily pretreated laryngeal squamous cell carcinoma who had an exceptional response to cetuximab monotherapy following the failure of immunotherapy with the PD-1 inhibitor nivolumab. We reviewed the literature for other cases of exceptional response to cetuximab, clinical studies investigating the combined or sequential administration of cetuximab and PD-1 inhibitors, and the mechanistic rationale for consideration of cetuximab as a potential salvage treatment after immunotherapy with PD-1 inhibitors. In addition to the specific epidermal growth factor receptor inhibitory effect, cetuximab, as an immunoglobulin G1 isotype, binds NK cells and elicits antibody-dependent cellular toxicity, triggering a domino of immunostimulatory, and immunoinhibitory effects that actually might decrease the cetuximab anticancer efficacy. However, in a tumor microenvironment exposed to previous treatment with a PD-1 inhibitor, the effects of the PD-1 inhibitor followed by cetuximab on innate and adaptative immune response appear to synergize. Specifically, persistent immune checkpoint inhibitors’ consequences may negate downstream immunosuppressive effects of cetuximab caused through PD-1/PD-L1 upregulation, making it a more potent treatment option. Besides the potential synergistic effect on antitumor immune response with previous immune checkpoint inhibitors therapy, cetuximab is the only targeted agent approved for treating R/M HNSCC, making it a most advantageous candidate for further treatment validation studies as salvage treatment post-immunotherapy." @default.
• W4386310918 created "2023-09-01" @default.
• W4386310918 creator A5003532001 @default.
• W4386310918 creator A5017828614 @default.
• W4386310918 creator A5022591120 @default.
• W4386310918 creator A5027196640 @default.
• W4386310918 creator A5028916358 @default.
• W4386310918 creator A5043587306 @default.
• W4386310918 creator A5046093849 @default.
• W4386310918 creator A5048496379 @default.
• W4386310918 creator A5055929591 @default.
• W4386310918 creator A5065584100 @default.
• W4386310918 creator A5067036623 @default.
• W4386310918 creator A5073460085 @default.
• W4386310918 creator A5085846057 @default.
• W4386310918 date "2023-01-01" @default.
• W4386310918 modified "2023-09-27" @default.
• W4386310918 title "Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature" @default.
• W4386310918 cites W1757407923 @default.
• W4386310918 cites W1761824857 @default.
• W4386310918 cites W1839071868 @default.
• W4386310918 cites W2010121426 @default.
• W4386310918 cites W2027536435 @default.
• W4386310918 cites W2033296826 @default.
• W4386310918 cites W2036392108 @default.
• W4386310918 cites W2057965214 @default.
• W4386310918 cites W2082636029 @default.
• W4386310918 cites W2099609050 @default.
• W4386310918 cites W2110860588 @default.
• W4386310918 cites W2112845420 @default.
• W4386310918 cites W2116869271 @default.
• W4386310918 cites W2136871952 @default.
• W4386310918 cites W2163196794 @default.
• W4386310918 cites W2163814058 @default.
• W4386310918 cites W2245249033 @default.
• W4386310918 cites W2261247786 @default.
• W4386310918 cites W2274310825 @default.
• W4386310918 cites W2529484692 @default.
• W4386310918 cites W2546767955 @default.
• W4386310918 cites W2588644110 @default.
• W4386310918 cites W2602907503 @default.
• W4386310918 cites W2607191617 @default.
• W4386310918 cites W2620740965 @default.
• W4386310918 cites W2744409114 @default.
• W4386310918 cites W2775469584 @default.
• W4386310918 cites W2790544349 @default.
• W4386310918 cites W2799372507 @default.
• W4386310918 cites W2800628858 @default.
• W4386310918 cites W2896455461 @default.
• W4386310918 cites W2901903079 @default.
• W4386310918 cites W2903493423 @default.
• W4386310918 cites W2905201605 @default.
• W4386310918 cites W2906118846 @default.
• W4386310918 cites W2916312593 @default.
• W4386310918 cites W2944058281 @default.
• W4386310918 cites W2945697541 @default.
• W4386310918 cites W2946611948 @default.
• W4386310918 cites W2955084311 @default.
• W4386310918 cites W2975889253 @default.
• W4386310918 cites W2986633517 @default.
• W4386310918 cites W2990704506 @default.
• W4386310918 cites W2994808935 @default.
• W4386310918 cites W3015847046 @default.
• W4386310918 cites W3027800442 @default.
• W4386310918 cites W3041891326 @default.
• W4386310918 cites W3049259283 @default.
• W4386310918 cites W3088991262 @default.
• W4386310918 cites W3093167374 @default.
• W4386310918 cites W3107533236 @default.
• W4386310918 cites W3133737650 @default.
• W4386310918 cites W3133969996 @default.
• W4386310918 cites W3160114067 @default.
• W4386310918 cites W3165579841 @default.
• W4386310918 cites W3166757885 @default.
• W4386310918 cites W3169513331 @default.
• W4386310918 cites W3208709932 @default.
• W4386310918 cites W3209858902 @default.
• W4386310918 cites W4221101481 @default.
• W4386310918 cites W4304474516 @default.
• W4386310918 cites W4306411248 @default.
• W4386310918 cites W4310592256 @default.
• W4386310918 cites W4313372174 @default.
• W4386310918 cites W4317477899 @default.
• W4386310918 cites W4317733417 @default.
• W4386310918 doi "https://doi.org/10.1177/17588359231193722" @default.
• W4386310918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37667781" @default.
• W4386310918 hasPublicationYear "2023" @default.
• W4386310918 type Work @default.
• W4386310918 citedByCount "0" @default.
• W4386310918 crossrefType "journal-article" @default.
• W4386310918 hasAuthorship W4386310918A5003532001 @default.
• W4386310918 hasAuthorship W4386310918A5017828614 @default.
• W4386310918 hasAuthorship W4386310918A5022591120 @default.
• W4386310918 hasAuthorship W4386310918A5027196640 @default.
• W4386310918 hasAuthorship W4386310918A5028916358 @default.
• W4386310918 hasAuthorship W4386310918A5043587306 @default.
• W4386310918 hasAuthorship W4386310918A5046093849 @default.
• W4386310918 hasAuthorship W4386310918A5048496379 @default.
• W4386310918 hasAuthorship W4386310918A5055929591 @default.
• W4386310918 hasAuthorship W4386310918A5065584100 @default.

• next